NEW YORK (
CHANGE IN RATINGS
(ATHN - Get Report)
rated new Buy at Sterne Agee. $71 price target. Focus on accretive outcome of a stronger brand and cloud based network.
downgraded at Needham from Buy to Hold, Needham said. Valuation call, as the stock is up 24% year-to-date.
downgraded at Wunderlich from Hold to Sell, Wunderlich said. $23 price target. Company is facing increased competition, which could cut into near-term growth.
(CY - Get Report)
downgraded at Needham from Buy to Hold, Needham said. Valuation call, based on a $20 price target.
(ETR - Get Report)
downgraded at Jefferies to Hold from Buy at Jefferies. $75 price target. Revised assessment of regulatory risk.
upgraded to buy at TheStreet Ratings.
downgraded at Ticonderoga from Buy to Neutral, Ticonderoga said. Valuation call.
(IPG - Get Report)
rated new Underperform at Jefferies. $9 price target. Low organic growth.
(KLAC - Get Report)
upgraded at Citigroup to Buy from Neutral, Citigroup said. $65 price target. Inspection and metrology targets the sweet spot of escalating foundry capital intensity.
rated new Outperform at Baird. $34 price target. Company has substantial growth prospects.
rated new Buy at Goldman. $28 price target. Permian basin should drive near-term growth for the company.
AllScripts Healthcare Solutions
rated new Buy at Sterne Agee. $24 price target. Leading electronic health record vendor.
upgraded at Citigroup to Buy from Neutral, Citigroup said. $60 price target. High probability LRCX-NVLS merger goes through mid year.
rated new Hold at Jefferies. $41 price target. Will face challenges given it generates over 80% of sales in US and Europe.
(POT - Get Report)
downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Valuation call, based on a $48 price target.
downgraded at Stifel from Buy to Hold, Stifel Nicolaus said. Valuation call. Stock trades at a premium to its peers and there are downside risks to underlying oil prices.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call, as the stock is up 35% over the past three months. $46 price target.